Innate Pharma S.A.
IPHA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IPHA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IPHA
Innate Pharma S.A. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, primarily through its proprietary ANKET platform and partnerships with AstraZeneca and Sanofi.
Key risk: Dependence on AstraZeneca
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 5 clinical trials for Innate Pharma S.A..
Innate Pharma S.A. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, primarily through its proprietary ANKET platform and partnerships with AstraZeneca and Sanofi.
- As of December 31, 2025, Innate Pharma had cash, cash equivalents, short-term investments and non-current financial assets of €44.8 million, with expected runway into the third quarter of 2026 [sec · filed 2026-04-01].
- The company's near-term prospects depend heavily on AstraZeneca's successful clinical development and commercialization of monalizumab, as well as the clinical success of its 13 other product candidates [sec · filed 2026-04-01].
- Innate Pharma's pipeline includes clinical-stage candidates monalizumab, lacutamab, IPH5301, IPH6501, IPH4502, and partnered assets IPH6401/SAR'514 (with Sanofi) and IPH62 [sec · filed 2026-04-01].
- The company expects its main near- and medium-term income sources to be payments from license and collaboration agreements (including AstraZeneca and Sanofi) and government grants/research tax credits [sec · filed 2026-04-01].
- Innate Pharma has incurred significant operational losses and may need additional financing to complete development and commercialization of its product candidates [sec · filed 2026-04-01].
What works
- Innate Pharma has established strategic collaborations with major biopharmaceutical companies AstraZeneca and Sanofi, which provide funding and development expertise for key assets like monalizumab and IPH6401/SAR'514 [sec · filed 2026-04-01].
- The company's innovative ANKET platform, which includes tri-specific and tetra-specific antibody formats, supports a diversified pipeline of product candidates [sec · filed 2026-04-01].
- Innate Pharma has multiple clinical-stage programs (monalizumab, lacutamab, IPH5301, IPH6501, IPH4502) and partnered assets, reducing reliance on any single candidate [sec · filed 2026-04-01].
What to weigh
- Innate Pharma's near-term prospects are heavily dependent on AstraZeneca's successful development and commercialization of monalizumab, over which the company has limited control [sec · filed 2026-04-01].
- The company has a history of significant operating losses and expects to continue incurring losses, with cash runway only until the third quarter of 2026, necessitating additional financing [sec · filed 2026-04-01].
- Most of Innate Pharma's product candidates are in early stages of development, and biopharmaceutical development involves high uncertainty; promising early results do not guarantee eventual approval or commercialization [sec · filed 2026-04-01].
- The company's innovative ANKET platform is not yet approved, and its product candidates are often developed in combination with other unapproved therapies, adding regulatory and clinical risk [sec · filed 2026-04-01].
From the filings
Quoted directly from source documents.
Innate Pharma's near-term prospects depend on AstraZeneca's success with monalizumab and clinical development of other candidates.
“Its near-term prospects depend heavily on AstraZeneca's successful clinical development and commercialization of monalizumab, as well as the successful clinical development of its 13 other product candidates.”
SEC filings · April 1, 2026
The company had €44.8 million in cash and equivalents as of December 31, 2025, with runway into Q3 2026.
“As of December 31, 2025, the Company had cash, cash equivalents, short-term investments and non-current financial assets of €44.8 million. The Company believes its cash, cash equivalents, short-term investments and non-current financial assets, together with its cash flow from operations, will be sufficient to fund its operations until third quarter 2026.”
SEC filings · April 1, 2026
The company's product candidates are in early stages and development involves high uncertainty.
“Biopharmaceutical development involves a high degree of uncertainty and most of the product candidates are in early stages of development, which makes it d”
SEC filings · April 1, 2026
Risks & what to watch (4)›
Key risks
- Dependence on AstraZeneca — Near-term success hinges on AstraZeneca's development and commercialization of monalizumab, over which Innate has limited control [sec · filed 2026-04-01].
- Cash runway limited — Cash runway only until Q3 2026; additional financing needed to complete development and commercialization [sec · filed 2026-04-01].
- Early-stage pipeline — Most candidates are in early development; high uncertainty of clinical success and regulatory approval [sec · filed 2026-04-01].
- Reliance on collaborations — Future development and marketing depend on partners' commitment; interruption of collaboration income could materially affect business [sec · filed 2026-04-01].
What to watch
- Progress of AstraZeneca's clinical trials for monalizumab and any regulatory milestones [sec · filed 2026-04-01].
- Innate Pharma's ability to secure additional financing before cash runway ends in Q3 2026 [sec · filed 2026-04-01].
- Clinical data readouts for key pipeline candidates including lacutamab, IPH5301, IPH6501, and IPH4502 [sec · filed 2026-04-01].
- Updates on Sanofi partnership for IPH6401/SAR'514 and IPH62 development [sec · filed 2026-04-01].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Innate Pharma S.A. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Innate Pharma S.A. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
1.9 months
OCF -$53M · Net income -$49M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$130K
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 43,524 | $56K |
| jane street group, llc | 43,365 | $56K |
| millennium management llc | 10,064 | $13K |
| rhumbline advisers | 4,734 | $6K |
| gamma investing llc | 240 | $307 |
| farther finance advisors, llc | 10 | $14 |
Short Interest
as of May 21, 2026- % of float
- 0.1%
- Days to cover
- 3.2
- Shares short
- 90,515
- Daily short volume (Aug 7, 2026)
- 19.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IPHA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Innate Pharma S.A.?
Innate Pharma S.A. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, primarily through its proprietary ANKET platform and partnerships with AstraZeneca and Sanofi.
Who is the CEO of Innate Pharma S.A.?
Mr. Jonathan E. Dickinson B.Sc., M.B.A. is the chief executive officer of Innate Pharma S.A. (IPHA).
Where is Innate Pharma S.A. headquartered?
Innate Pharma S.A. (IPHA) is headquartered in Marseille, France.
What therapeutic areas does Innate Pharma S.A. focus on?
Innate Pharma S.A. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.